Triapine (3-aminopyridine-2-carboxaldehyde- thiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity

• Published in: Biochemical pharmacology 2000-04, Vol.59 (8), p.983-991
• Main Authors: Finch, Rick A, Liu, Mao-Chin, Grill, Susan P, Rose, William C, Loomis, Regina, Vasquez, Karen M, Cheng, Yung-Chi, Sartorelli, Alan C
• Format: Article
• Language: English
• Subjects: Animals; antagonists; Antineoplastic agents; Antineoplastic Agents - pharmacokinetics; Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; antineoplastic agents combined; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biological and medical sciences; Blood-Brain Barrier; Cell Division - drug effects; DNA - biosynthesis; DNA - drug effects; Drug Resistance, Neoplasm; Enzyme Inhibitors - pharmacokinetics; Enzyme Inhibitors - pharmacology; Enzyme Inhibitors - therapeutic use; General aspects; Humans; Hydroxyurea - pharmacology; inhibition of DNA synthesis; inhibitors; KB Cells; L1210 leukemia cells; Leukemia L1210 - drug therapy; Medical sciences; Mice; Neoplasm Transplantation; Neoplasms, Experimental - drug therapy; Pharmacology. Drug treatments; Pyridines - pharmacokinetics; Pyridines - pharmacology; Pyridines - therapeutic use; ribonucleotide reductase; Ribonucleotide Reductases - antagonists & inhibitors; Thiosemicarbazones - pharmacokinetics; Thiosemicarbazones - pharmacology; Thiosemicarbazones - therapeutic use; Triapine 3-AP; Tumor Cells, Cultured; α-( N)-heterocyclic carboxaldehyde thiosemicarbazone
• ISSN: 0006-2952; 1873-2968
• DOI: 10.1016/S0006-2952(99)00419-0

Previous studies from our laboratories have shown that (a) Triapine ™ is a potent inhibitor of ribonucleotide reductase activity and (b) hydroxyurea-resistant L1210 leukemia cells are fully sensitive to Triapine. In an analogous manner, Triapine was similarly active against the wild-type and a hydroxyurea-resistant subline of the human KB nasopharyngeal carcinoma. Triapine was active in vivo against the L1210 leukemia over a broad range of dosages and was curative for some mice. This agent also caused pronounced inhibition of the growth of the murine M109 lung carcinoma and human A2780 ovarian carcinoma xenografts in mice. Optimum anticancer activity required twice daily dosing due to the duration of inhibition of DNA synthesis which lasted about 10 hr in L1210 cells treated with Triapine in vivo. DNA synthesis in normal mouse tissues (i.e. duodenum and bone marrow) uniformly recovered faster than that in L1210 leukemia cells, demonstrating a pharmacological basis for the therapeutic index of this agent. Triapine was more potent than hydroxyurea in inhibiting DNA synthesis in L1210 cells in vivo, and the effects of Triapine were more pronounced. In addition, the duration of the inhibition of DNA synthesis in leukemia cells from mice treated with Triapine was considerably longer than in those from animals treated with hydroxyurea. Combination of Triapine with various classes of agents that damage DNA (e.g. etoposide, cisplatin, doxorubicin, and 1-acetyl-1,2-bis(methylsulfonyl)-2-(2-chloroethyl)hydrazine) resulted in synergistic inhibition of the L1210 leukemia, producing long-term survivors of tumor-bearing mice treated with several dosage levels of the combinations, whereas no enhancement of survival was found when Triapine was combined with gemcitabine or cytosine arabinoside. The findings demonstrate the superiority of Triapine over hydroxyurea as an anticancer agent and further suggest that prevention by Triapine of repair of DNA lesions created by agents that damage DNA may result in efficacious drug combinations for the treatment of cancer.